Botulinum toxin A (BT-A) versus low-level laser therapy (LLLT) in chronic migraine treatment: a comparison

ABSTRACT The aim of this work was to evaluate patients with chronic migraine treated with botulinum toxin A (BT-A) and compare this with low level laser therapy (LLLT), referencing: pain days, pain intensity, intake of drugs/self-medication, anxiety and sleep disorders. Methods: Patients were random...

Full description

Saved in:
Bibliographic Details
Published in:Arquivos de neuro-psiquiatria 2018-10, Vol.76 (10), p.663-667
Main Authors: Loeb, Luana Mazzacoratti, Amorim, Rebeca Padrão, Mazzacoratti, Maria da Graça Naffah, Scorza, Fulvio Alexandre, Peres, Mario Fernando Prieto
Format: Article
Language:English
Subjects:
Anxiety
Botulinum toxin
Botulinum toxin type A
botulism
Headache
Lasers
low level laser therapy
Migraine
Migraine disorders
NEUROSCIENCES
Pain
Patients
PSYCHIATRY
Sleep
Sleep disorders
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT The aim of this work was to evaluate patients with chronic migraine treated with botulinum toxin A (BT-A) and compare this with low level laser therapy (LLLT), referencing: pain days, pain intensity, intake of drugs/self-medication, anxiety and sleep disorders. Methods: Patients were randomized into two groups: BT-A group (n = 18) and LLLT group (n = 18). Each patient kept three pain diaries: one before (baseline) (30 days), one during treatment (30 days) and one after the post-treatment phase (30 days). Repeated ANOVA plus the Bonferroni post-test, Student's t test, and factorial analysis were applied, and p < 0.05 was accepted as significant. Results: Our data showed that both treatments were able to reduce headache days, acute medication intake and decrease the intensity of pain. Anxiety was reduced in the BT-A group, while sleep disturbance was reduced in the LLLT group. Conclusion: Our data showed that both treatments can be used to treat chronic migraine, without notable differences between them.
ISSN:0004-282X
1678-4227
1678-4227
DOI:10.1590/0004-282X20180109